ARTICLE | Product Development
BioCentury’s latest Clinical Report also analyzes results from Alector, NewAmsterdam and Pyxis that led shares to slip, and more
By Lauren Martz, Executive Director, Biopharma Intelligence, and Selina Koch, Executive Editor
November 27, 2024 1:15 AM UTC
Biohaven Ltd. (NASDAQ:BHVN) is changing direction after spinal muscular atrophy (SMA) candidate taldefgrobep alpha failed to meet the primary endpoint as adjunctive therapy in the Phase III RESILIENCE study. In addition to analyzing data in biomarker-defined patient populations, the company is accelerating development for obesity.
Biohaven reported that taldefgrobep, an inhibitor of active myostatin that also blocks activin A and other targets, led to a potentially clinically meaningful but not statistically significant improvement in 206 ambulatory and non-ambulatory SMA patients, as measured by the Motor Function Measurement-32 scale (MFM-32), compared with placebo…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/654330/biohaven-s-phase-iii-sma-miss-was-it-the-target-or-the-trial-design